Like_老虎社区_美港股上老虎

jub
2021-12-23

Labcorp Bolsters Liquid Biopsy Capabilities With $450M PGDx Acquisition<blockquote>Labcorp 以 4.5 亿美元收购 PGDx 增强液体活检能力</blockquote>

Laboratory Corp of America Holdings has agreed to acquire Personal Genome Diagnostics Inc (PGDx), a

Labcorp Bolsters Liquid Biopsy Capabilities With $450M PGDx Acquisition<blockquote>Labcorp 以 4.5 亿美元收购 PGDx 增强液体活检能力</blockquote>

免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。

推荐
最新

暂无评论

热议股票

{"i18n":{"language":"zh_CN"},"data":{"magic":2,"id":698047048,"tweetId":"698047048","gmtCreate":1640269579491,"gmtModify":1640269579622,"author":{"id":3578715828142222,"idStr":"3578715828142222","authorId":3578715828142222,"authorIdStr":"3578715828142222","name":"jub","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":12,"crmLevelSwitch":0,"individualDisplayBadges":[],"wearingBadges":[],"fanSize":8,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"title":"","extraTitle":"","html":"<html><head></head><body><p>Like</p></body></html>","htmlText":"<html><head></head><body><p>Like</p></body></html>","text":"Like","highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":1,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/698047048","repostId":1133161256,"repostType":4,"repost":{"id":"1133161256","kind":"news","weMediaInfo":{"introduction":"Stock Market Quotes, Business News, Financial News, Trading Ideas, and Stock Research by Professionals","home_visible":0,"media_name":"Benzinga Earnings","id":"1052270027","head_image":"https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa"},"pubTimestamp":1640269130,"share":"https://www.laohunote.com/m/news/1133161256?lang=zh_CN&edition=full","pubTime":"2021-12-23 22:18","market":"us","language":"en","title":"Labcorp Bolsters Liquid Biopsy Capabilities With $450M PGDx Acquisition<blockquote>Labcorp 以 4.5 亿美元收购 PGDx 增强液体活检能力</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1133161256","media":"Benzinga Earnings","summary":"Laboratory Corp of America Holdings has agreed to acquire Personal Genome Diagnostics Inc (PGDx), a ","content":"<p><b>Laboratory Corp of America Holdings</b>&nbsp;has agreed to acquire&nbsp;Personal Genome Diagnostics Inc (PGDx), a cancer genomics firm with a portfolio of comprehensive liquid biopsy and tissue-based products.</p><p><blockquote><b>美国实验室控股公司</b>已同意收购 Personal Genome Diagnostics Inc (PGDx)，这是一家癌症基因组学公司，拥有全面的液体活检和组织产品组合。</blockquote></p><p> <ul>  <li>Labcorp will pay $450 million in cash at closing and up to an additional $125 million on achieving future performance milestones.</li>  <li>The addition of PGDx complements &amp; accelerates Labcorp’s existing liquid biopsy capabilities and expands its oncology portfolio of next-generation sequencing (NGS)-based genomic profiling capabilities.</li>  <li>PGDx offers the only diagnostic kit cleared by the FDA for pan-solid cancer comprehensive tumor profiling using a 500+ gene panel.</li>  <li>PGDx 2021 revenues are expected to be approximately $22 million, with projected revenues for 2022 expected to be nearly $40 million.</li>  <li>Labcorp expects the acquisition to be slightly dilutive to its adjusted EPS over the next couple of years and provide returns over its cost of capital by year five.</li>  <li>The transaction is expected to close in 1H of 2022.</li>  <li><b>Price Action</b>: LH shares closed higher by 0.54% at $304.22 on Wednesday.</li> </ul></p><p><blockquote><ul><li>Labcorp 将在交易结束时支付 4.5 亿美元现金，并在实现未来业绩里程碑时额外支付高达 1.25 亿美元。</li><li>PGDx 的加入补充并加速了 Labcorp 现有的液体活检能力，并扩展了其基于下一代测序 (NGS) 的基因组分析能力的肿瘤学产品组合。</li><li>PGDx提供了唯一一个由FDA批准的诊断试剂盒，用于使用500多个基因面板进行泛实体癌综合肿瘤分析。</li><li>PGDx 2021 年收入预计约为 2200 万美元，2022 年收入预计接近 4000 万美元。</li><li>Labcorp 预计此次收购将在未来几年内略微稀释其调整后每股收益，并在第五年提供超过资本成本的回报。</li><li>该交易预计将于2022年上半年完成。</li><li><b>价格行为</b>: LH 股价周三收盘上涨 0.54%，至 304.22 美元。</li></ul></blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Labcorp Bolsters Liquid Biopsy Capabilities With $450M PGDx Acquisition<blockquote>Labcorp 以 4.5 亿美元收购 PGDx 增强液体活检能力</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nLabcorp Bolsters Liquid Biopsy Capabilities With $450M PGDx Acquisition<blockquote>Labcorp 以 4.5 亿美元收购 PGDx 增强液体活检能力</blockquote>\n</h2>\n<h4 class=\"meta\">\n<div class=\"head\" \">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Benzinga Earnings </p>\n<p class=\"h-time smaller\">2021-12-23 22:18</p>\n</div>\n</div>\n</h4>\n</header>\n<article>\n<p><b>Laboratory Corp of America Holdings</b>&nbsp;has agreed to acquire&nbsp;Personal Genome Diagnostics Inc (PGDx), a cancer genomics firm with a portfolio of comprehensive liquid biopsy and tissue-based products.</p><p><blockquote><b>美国实验室控股公司</b>已同意收购 Personal Genome Diagnostics Inc (PGDx)，这是一家癌症基因组学公司，拥有全面的液体活检和组织产品组合。</blockquote></p><p> <ul>  <li>Labcorp will pay $450 million in cash at closing and up to an additional $125 million on achieving future performance milestones.</li>  <li>The addition of PGDx complements &amp; accelerates Labcorp’s existing liquid biopsy capabilities and expands its oncology portfolio of next-generation sequencing (NGS)-based genomic profiling capabilities.</li>  <li>PGDx offers the only diagnostic kit cleared by the FDA for pan-solid cancer comprehensive tumor profiling using a 500+ gene panel.</li>  <li>PGDx 2021 revenues are expected to be approximately $22 million, with projected revenues for 2022 expected to be nearly $40 million.</li>  <li>Labcorp expects the acquisition to be slightly dilutive to its adjusted EPS over the next couple of years and provide returns over its cost of capital by year five.</li>  <li>The transaction is expected to close in 1H of 2022.</li>  <li><b>Price Action</b>: LH shares closed higher by 0.54% at $304.22 on Wednesday.</li> </ul></p><p><blockquote><ul><li>Labcorp 将在交易结束时支付 4.5 亿美元现金，并在实现未来业绩里程碑时额外支付高达 1.25 亿美元。</li><li>PGDx 的加入补充并加速了 Labcorp 现有的液体活检能力，并扩展了其基于下一代测序 (NGS) 的基因组分析能力的肿瘤学产品组合。</li><li>PGDx提供了唯一一个由FDA批准的诊断试剂盒，用于使用500多个基因面板进行泛实体癌综合肿瘤分析。</li><li>PGDx 2021 年收入预计约为 2200 万美元，2022 年收入预计接近 4000 万美元。</li><li>Labcorp 预计此次收购将在未来几年内略微稀释其调整后每股收益，并在第五年提供超过资本成本的回报。</li><li>该交易预计将于2022年上半年完成。</li><li><b>价格行为</b>: LH 股价周三收盘上涨 0.54%，至 304.22 美元。</li></ul></blockquote></p><p></p>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"LH":"徕博科"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1133161256","content_text":"Laboratory Corp of America Holdings has agreed to acquire Personal Genome Diagnostics Inc (PGDx), a cancer genomics firm with a portfolio of comprehensive liquid biopsy and tissue-based products.\n\nLabcorp will pay $450 million in cash at closing and up to an additional $125 million on achieving future performance milestones.\nThe addition of PGDx complements & accelerates Labcorp’s existing liquid biopsy capabilities and expands its oncology portfolio of next-generation sequencing (NGS)-based genomic profiling capabilities.\nPGDx offers the only diagnostic kit cleared by the FDA for pan-solid cancer comprehensive tumor profiling using a 500+ gene panel.\nPGDx 2021 revenues are expected to be approximately $22 million, with projected revenues for 2022 expected to be nearly $40 million.\nLabcorp expects the acquisition to be slightly dilutive to its adjusted EPS over the next couple of years and provide returns over its cost of capital by year five.\nThe transaction is expected to close in 1H of 2022.\nPrice Action: LH shares closed higher by 0.54% at $304.22 on Wednesday.","news_type":1,"symbols_score_info":{"LH":0.9}},"isVote":1,"tweetType":1,"viewCount":3196,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":4,"subscribersOnly":false,"subscribersOnlyAccessible":false,"xxTargetLangEnum":"ZH_CN"},"commentList":[],"hasMoreComment":false,"orderType":2}

Labcorp Bolsters Liquid Biopsy Capabilities With $450M PGDx Acquisition<blockquote>Labcorp 以 4.5 亿美元收购 PGDx 增强液体活检能力</blockquote>

评论（1）

热议股票